California Stem Cell Agency: "Valley of Death" Cash Will Get Treatments To Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
But biotechs shouldn't expect salvation, as an anticipated loan program is off to a slow start.
You may also be interested in...
Spinal Cord Injury Product Makes Progress As Asterias Picks Up Where Geron Left Off
New endpoint guidelines – and matching grant funding from the California Institute for Regenerative Medicine – enhance possibility of demonstrating functional improvement in the Phase I/IIa trial of the stem-cell therapeutic.
Sangamo Brushes Off Phase IIb Diabetic Neuropathy Failure
The biotech looks to new targets -- HIV and monogenic diseases -- after a disappointing trial in diabetic neuropathy.
Sangamo Brushes Off Phase IIb Diabetic Neuropathy Failure
The biotech looks to new targets -- HIV and monogenic diseases -- after a disappointing trial in diabetic neuropathy.